Evaluating the potential of sNfL as a biomarker in MS management in the UK: insights from SUNLIT survey Authors: Sharmilee Gnanapavan, Tarunya Arun, Paul Gallagher, Michael Rushworth, Jade Marsh, Nazanin R. Kondori Published: 2025 ABSTRACT BackgroundCurrent evidence supports the use of NfL as a biomarker for neuroaxonal damage in multiple sclerosis (MS), but translation from clinical trials to clinical practice is needed to guide optimal patient management.MethodsThe SUNLIT survey, led by the Novartis medical science liaisons in collaboration with leading MS experts, aimed to assess the utility of sNfL as a biomarker for MS in routine clinical practice within UK. The survey included key questions to assess the clinician’s opinion and level of understanding of sNfL, experience with sNfL measurement, potential drivers and barriers to sNfL testing, identification of potential patient targets and potential impact of sNfL testing on the management of MS, and the role of guidelines for on the adoption of sNfL into clinical practice for MS management across the UK.ResultsA total of 86 clinicians (neurologists specialising in MS, n = 45; MS nurse practitioners, n = 41) from the UK participated in the survey. All HCPs responded to all the survey questions. The findings from the neurologist interviews were positive, supporting the use of sNfL if available (98%). Neurologists perceived that sNfL testing could be used at multiple points in the MS patient management pathway, commonly at treatment switch or initiation, and that it could potentially reduce frequency of MRI scans. The majority of clinicians demonstrated a moderate level of understanding regarding sNfL data in MS; with most clinicians perceiving a need for additional education, and low awareness of existing guidelines on sNfL testing in MS management. Access to sNfL testing and potential confounders like age and BMI were identified as potential barriers to its implementation.ConclusionsThe SUNLIT survey provides important insights into the opinion of HCPs on the potential role of sNfL as a biomarker for MS in the UK. The high level of interest in sNfL testing, coupled with the identified barriers and need for additional education, highlights the need for concerted efforts to support the adoption of sNfL in clinical practice. By addressing these challenges, sNfL has the potential to significantly enhance the management of MS, providing clinicians with a valuable tool for monitoring disease activity and informing treatment decisions.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12883-025-04547-0. Introduction Multiple sclerosis (MS) is a chronic disease of the central nervous system characterised by heterogeneous clinical symptoms and focal inflammation, axonal loss, gliosis and demyelination [1]. With remarkable advances in disease-modifying therapies (DMTs) used for the management of MS, it is increasingly recognised that early optimal control of inflammatory activity offers the best long-term outcome [2–5]. However, even for patients who achieve ‘no evidence of disease activity’ status, according to standard clinical and magnetic resonance imaging (MRI) monitoring [6, 7], a proportion of them will continue to experience some level of cumulative damage to the brain and disease progression that is clinically silent [8, 9]. Despite the availability of diagnostic and safety biomarkers, there exists a need for more accessible biomarkers from blood or other body fluids that can help in detecting and prognosticating subclinical levels of disease activity, with the aim of protecting brain integrity and delaying irreversible neurological damage [10–12]. Neurofilament light chain (NfL) is a sensitive but unspecific marker of axonal injury released in response to axonal damage in the central nervous system because of inflammatory, neurodegenerative, traumatic or vascular injury and has emerged as a promising marker of neuro-axonal injury in neurological diseases including MS [13–15]. NfL has shown potential utility for prognosticating MS and monitoring MS disease activity and treatment response [16–25]. Advancements in the ultrasensitive detection of biomarkers have enabled the measurement of NfL in blood (serum/plasma), which correlates with NfL levels in the cerebrospinal fluid (CSF) [26]. Being a tissue-specific, objective and quantitative measure of recent neuronal loss, NfL has the potential to address unmet needs for blood biomarkers to predict disease worsening and capture response to DMTs [17, 23, 27]. Furthermore, serum NfL (sNfL), which is a relatively non-invasive and inexpensive marker, can be advantageous over traditional measures of MS disease progression. An international expert consensus supports the use of NfL as a clinically relevant biomarker of short- and long-term prognoses in people with relapsing remitting MS (RRMS), in conjunction with existing clinical and imaging tools [17, 25]. While sNfL has been used in clinical trials for several years [13], there is a need to transfer clinical trial experience to clinical practice to help guide improvements in MS patient management in the United Kingdom (UK). The objective of the SerUm NeurofiLament In UK clinical PracTice (SUNLIT) survey is to gain insights into the potential future use and value of NfL level measurements in blood as a biomarker of MS as well as potential barriers in the adoption of NfL in clinical practice in the UK. Methods Survey design and participants SUNLIT was a survey designed to map perceptions and existing viewpoints concerning sNfL testing in the context of MS management across the neurology community of MS specialists in the UK. This survey led by the Novartis medical science liaisons included a non-promotional questionnaire developed by the Novartis medical team in collaboration with leading MS experts. The survey was hosted and analysed by Adelphi Research. The questionnaire was administered to healthcare professionals (HCPs) from December 2023 to March 2024. HCPs who managed > 50 patients with MS in the past year and were directly involved in the overall treatment and management of patients with MS were included in the survey. Neurologists in the UK completed a 45-minute survey in a face-to-face or virtual setting and were interviewed by a Novartis medical science liaison on 18 questions on different parameters including the understanding of sNfL testing and its value in clinical practice and MS management in the UK. Respondents have not been incentivised for their participation to avoid potential sponsorship bias. MS nurse specialists completed a shorter 15-minute survey either face-to-face or online either in the presence or absence of a Novartis medical science liaison on parameters including the understanding and clinical applicability of sNfL testing. Data were collected through the responses of eligible HCPs to the questionnaire in the form of a single answer, multiple answers or free text. Survey questionnaire The survey aimed to answer key questions to assess the clinician’s opinion and level of understanding of sNfL and experience with sNfL measurement, potential drivers and barriers to sNfL testing, identification of potential patient targets and potential impact of sNfL testing on the management of MS and the role of guidelines on the adoption of sNfL into clinical practice for MS management across the UK. The survey questionnaire is presented in the supplementary material (supplementary file 1). Statistical analysis As only qualitative data were collected, the results are presented descriptively, and categorical variables are summarised as frequencies and percentages. Results A total of 86 clinicians (neurologists specialising in MS, n = 45; MS nurse practitioners, n = 41; response rate of 25% among the clinicians) from the UK participated in the survey. Survey respondents were based across 57 MS centres. There were 36 centres with 1 MS clinician respondent, 15 centres had 2 respondents, 4 centres had 3 respondents, and 2 centres had 4 respondents. The geographical spread of the survey respondents is presented in the supplemental material (supplementary material 2). All HCPs responded to all the survey questions. Insights from the clinician surveys are discussed in the subsequent subsections. Insights from the doctors’ survey Doctors’ opinion and level of Understanding of and experience with sNfL measurement Most doctors (67%) reported an average understanding of the overall data on sNfL for MS (mean rank: 6) and sNfL as a biomarker in MS (mean rank: 6.8) on a scale ranging from 1 to 10 (1–3, poor; 4–7, average; 8–10, very good). Most clinicians perceived sNfL levels to be reflective of the acute inflammatory process (93%), followed by disability progression (67%) and conversion of RRMS to progressive MS (42%); most clinicians (85%) reported sNfL to be somewhat (36%) or extremely useful (49%) as a measure of disease activity. Moreover, 38% of the clinicians reported that they had performed sNfL testing, whereas 62% of the clinicians reported that they did not have any experience with sNfL testing (Fig. 1). None of the clinicians currently tested sNfL levels in all their patients, whereas a few clinicians (13%) currently tested sNfL levels in a subset of patients, 9% of clinicians measured sNfL levels in the past and 22% currently measured NfL levels in CSF (16% had experience with measuring NfL levels only in CSF). Fig. 1Level of experience with sNfL/NfL measurement in MS specialists: Most clinicians responded having no experience with sNfL testing. CSF, cerebrospinal fluid; NfL, neurofilament light chain; sNfL, serum neurofilament light chain Level of experience with sNfL/NfL measurement in MS specialists: Most clinicians responded having no experience with sNfL testing. CSF, cerebrospinal fluid; NfL, neurofilament light chain; sNfL, serum neurofilament light chain Drivers of and barriers to potential future uptake of sNfL and potential target patient types A majority of clinicians (98%) showed an interest in measuring sNfL if the test was made available for free suggestive of a high appetite for the adoption of sNfL. The top five mentions of perceived benefits and risks of incorporating sNfL testing in MS management as perceived by MS specialists are outlined in Fig. 2. Fig. 2Perceived benefits and risks of incorporating sNfL testing in MS management. MS, multiple sclerosis; sNfL, serum neurofilament light chain; SPMS, secondary progressive multiple sclerosis Perceived benefits and risks of incorporating sNfL testing in MS management. MS, multiple sclerosis; sNfL, serum neurofilament light chain; SPMS, secondary progressive multiple sclerosis Access to sNfL testing (76%), natural confounders of sNfL (71%) and variance in age and body mass index (BMI; 64%) were identified as top potential barriers to the implementation and interpretation of sNfL testing in clinical practice. All clinicians foresee at least one barrier to sNfL testing (Fig. 3). Fig. 3Main barriers to sNfL testing. BMI, body mass index; MS, multiple sclerosis; sNfL, serum neurofilament light chain Main barriers to sNfL testing. BMI, body mass index; MS, multiple sclerosis; sNfL, serum neurofilament light chain Overall, treatment-naïve patients (71%) or those for whom treatment might be stopped or paused (67%) were the most frequently mentioned patient groups for sNfL testing by the clinicians. Clinicians without sNfL experience perceived the broadest role for sNfL testing across many different patient groups (Fig. 4). Fig. 4Key patient types for sNfL testing. CSF, cerebrospinal fluid; DMT, disease-modifying therapy; HET, high-efficacy therapy; NfL, neurofilament light chain; sNfL, serum neurofilament light chain Key patient types for sNfL testing. CSF, cerebrospinal fluid; DMT, disease-modifying therapy; HET, high-efficacy therapy; NfL, neurofilament light chain; sNfL, serum neurofilament light chain Potential impact of sNfL testing on MS management sNfL testing (mean rank: 8–10) was believed to confer the highest impact on monitoring response to treatment (49%), followed by decision-making when managing patients (24%) and treatment decision making (22%; Fig. 5). While sNfL testing was not expected to completely remove the need for MRI, most doctors (58%) expect sNfL testing to reduce the frequency of MRI. The survey results indicate that sNfL testing could potentially be used most commonly at treatment switch (82%) and then at treatment initiation (76%). This was followed by choice of DMT between the platform therapy and high-efficacy therapy (HET, 60%), stopping criteria (60%) and others such as at baseline or at any point when the disease activity is suspected or every 3 months (13%). Fig. 5Impact of sNfL was highest on monitoring response to treatment among different aspects of patient management. DMT, disease-modifying therapy; MS, multiple sclerosis; sNfL, serum neurofilament light chain Impact of sNfL was highest on monitoring response to treatment among different aspects of patient management. DMT, disease-modifying therapy; MS, multiple sclerosis; sNfL, serum neurofilament light chain Clinical consensus and the role of guidelines on the use of sNfL in clinical practice The survey highlighted that 78% of the participating doctors perceived the need for additional education, and those who did not have experience in sNfL testing perceived additional education as an extremely important factor. Despite there being a low awareness on the guidelines for the use of sNfL testing among doctors, most doctors (76%) anticipate reimbursement of sNfL testing within guidelines, suggesting a level of optimism regarding its future implementation in MS clinical care (Fig. 6). Fig. 6There is a low awareness on the guidelines for the use of sNfL testing among MS doctors. sNfL, serum neurofilament light chain; UK, United Kingdom There is a low awareness on the guidelines for the use of sNfL testing among MS doctors. sNfL, serum neurofilament light chain; UK, United Kingdom Insights from the nurses’ survey Of the 41 nurse practitioners interviewed, the majority perceived monitoring disease activity (73%) as a key benefit of sNfL testing, followed by the use of sNfL to monitor treatment response (61%), assist with treatment decision-making (56%), evaluate patients’ prognosis (51%) and confirm relapses (49%; Fig. 7). Although these perceived benefits were similar to those reported by the MS neurologists, the nurse practitioners felt that they had a low understanding of the prognostic value of sNfL testing (63%) and confidence in communicating the results of sNfL testing to patients (83%). Fig. 7Benefits of sNfL testing perceived by nurses: Similar to MS doctors, nurse practitioners perceived monitoring disease activity as a key benefit of sNfL testing. FND, functional neurological disorder; sNfL, serum neurofilament light chain Benefits of sNfL testing perceived by nurses: Similar to MS doctors, nurse practitioners perceived monitoring disease activity as a key benefit of sNfL testing. FND, functional neurological disorder; sNfL, serum neurofilament light chain Discussion Findings from the SUNLIT survey provide insights into the current perceptions and potential future use of sNfL as a biomarker for MS management in clinical practice in the UK. The survey results highlight several key points that are crucial for understanding the role of sNfL in MS management. Owing to their ability to reflect neuro-axonal injury in real time, neurofilaments, particularly NfL, is being widely investigated as an easily accessible biomarker in a myriad of neurological diseases including MS [16, 28]. The survey results suggested that 98% of clinicians expressed a desire to measure sNfL if the test was freely available, indicating a strong appetite for incorporating sNfL into routine clinical practice. However, the survey also identified several barriers to the implementation of sNfL testing in clinical practice, including access to testing, controlling for natural confounders such as age and BMI and a general lack of experience with sNfL testing among clinicians. These barriers must be considered and addressed to facilitate the widespread adoption of sNfL testing in MS management. While the advent of ultrasensitive assays such as SIMOA have paved the way to measure sNfL levels without the need for invasive CSF measurements, multiple challenges have hindered their translation into clinically approved diagnostic tests. Regulatory and quality requirements are often strict, and the stages of production and analytical and clinical validation are expensive. In addition, issues around comparisons across testing platforms (absolute values) and normalisation (reference ranges) to guide the interpretation of the results are needed [17, 28]. While age and BMI could be potential confounders for the interpretation of NfL, making it difficult to establish fixed cut-off levels, the use of a single sNfL threshold was prognostic of future lesion formation regardless of BMI and age in people with MS aged 18–55 years [29]. In addition, an increase in sNfL levels in older healthy controls may be masked by the higher baseline inflammatory activity observed in younger patients with MS, suggesting that age-based variation in sNfL levels may not be a relevant confounder in clinical practice in younger patients without comorbidities [16]. NfL is not specific to MS pathology, and its level can be elevated in other neurological and non-neurological comorbidities associated with neuronal loss or inflammation, which must be considered by clinicians while interpreting sNfL levels [17, 22]. Considering this, combining sNfL with other fluid biomarkers and clinical and MRI measures could be highly promising and can help guide personalised treatment decision-making [16]. Existing guidelines on the use of sNfL testing underline the ability of NfL to address a major unmet need for blood biomarkers to objectively predict disease worsening and monitor response to DMT in the management of MS, and provide a framework for how sNfL testing could be implemented into clinical practice for MS care [17, 25]. Building on this, the SUNLIT survey captured real-world clinician perspectives in the UK on sNfL testing, offering valuable insight into how MS specialists perceive its role in routine practice. Findings from the survey broadly aligned with the principles outlined in the available guidelines; namely, that sNfL is a practical adjunct to clinical and MRI monitoring, informative in assessing disease activity, useful for gauging prognosis, and helpful for monitoring treatment response. Many of the scenarios in which clinicians anticipated using sNfL, such as at treatment initiation, switching therapies, or investigating relapse recovery, closely mirror those recommended in the guidelines. Although the majority of respondents were unaware of the guidelines, their clinical reasoning and expectations around sNfL use were fairly consistent with the international panel’s recommendations. For instance, UK clinicians recognised important caveats related to sNFL testing as noted in the guidelines such as concerns around the specificity of sNfL findings, the need for assay consistency, and that interpretation should account for natural confounders. However, the survey results also highlighted several challenges related to real-world uptake and operational details. While the guidelines assume a degree of testing access and provide structured recommendations on when and how to measure sNfL, the survey results revealed low awareness of these guidelines and limited hands-on experience among clinicians, as well as concerns around availability and funding. Despite high interest, clinicians cited barriers such as lack of infrastructure, uncertainty around interpretation, and the need for further education. Hence there is a need for system-level support to bridge the gap between guideline recommendations and clinical reality. Overall, this highlights that efforts should be made to enhance testing education, availability, and funding in order to increase the likelihood of adoption in routine clinical practice. The survey highlighted the potential benefits of sNfL testing in MS management. Clinicians perceived sNfL as a valuable tool for monitoring disease activity, predicting relapses and informing treatment decisions consistent with previous findings from surveys that have evaluated the impact of sNfL implementation in routine clinical practice and existing guidelines [17, 25, 30, 31]. The ability of sNfL testing to provide a relatively inexpensive and non-invasive indication of MS disease activity, which can be repeated at regular intervals, offers a significant advantage over traditional MRI scans [17, 32]. This is particularly important given the recent recommendations to limit the use of gadolinium-based contrast agents for evaluating inflammatory disease activity [7]. The use of sNfL testing, whilst not replacing MRI, can potentially reduce the frequency of MRI use thus reducing the overall cost and resource burden associated with MS management guided by MRI. Furthermore, sNfL shows high stability at room temperature and in frozen blood samples and is not affected by thawing cycles or storage time, suggesting the potential for broad application of sNfL as a biomarker in MS [16]. Early results from real-world cohorts and clinical trials that have used sNfL as a marker and predictor of disease activity are encouraging [16, 33–40]. These findings underscore the potential of sNfL to enhance the management of MS by providing clinicians with a valuable biomarker and suggest the utility of sNfL measures across the patient pathway in MS including initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection [16]. Despite the promising potential of sNfL, the survey highlights the need for additional education and increased awareness around existing guidelines on the use of sNfL in MS management to support its use in clinical practice for MS management. Whilst most clinicians (78%) perceived the need for additional education on sNfL testing, particularly for those without prior experience, the majority (82%) were also not aware about existing guidelines on sNfL testing. This could be attributed to the fact that sNfL is not currently reimbursed and part of the management algorithm and is not part of daily routine clinical practice This underscores the need for additional training and the importance of educating clinicians on the existing guidelines on the use of sNfL in patients with MS to facilitate the integration of sNfL testing into routine practice for MS and a need for clear, standardised guidelines on the use of sNfL in clinical practice. Limitations of the survey include a small sample size. While the survey (which was an unpaid activity involving up to 45 min of doctors’ time and up to 10 min for MS specialist nurses) aimed to include MS clinicians across the UK, a response rate of ~ 25% was registered among the clinicians. Extrapolating the survey results to the entire UK MS care community needs to be done with caution. It is important to note that these findings are based around obtaining a more granular understanding of the MS disease process. But it may lead to over-reliance or misinterpretation leading to wrong management decisions, particularly in view of existing known confounders. In conclusion, the SUNLIT survey provides important insights into the opinion of HCPs on the potential role of sNfL as a biomarker for MS in the UK. The high level of interest in sNfL testing, coupled with the identified barriers and need for additional education, highlights the need for concerted efforts to support the adoption of sNfL in clinical practice. Future studies are required to establish a consensus on cut-off thresholds for high sNfL values, scrutinize the patient-level predictive accuracy of sNfL, and explore composite predictive models combining sNfL values with measures of clinical status and MRI activity. [17] By addressing these challenges, sNfL has the potential to significantly enhance the management of MS, providing clinicians with a valuable tool for monitoring disease activity and informing treatment decisions. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.